Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Benzer Materyaller

• Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
  Yazar:: Wang, Wei, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
  Yazar:: Chen, Z, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
  Yazar:: Gong, Zimu, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
  Yazar:: Prescott, Hillary, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
  Yazar:: Jabbour, Elias J., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)